A Phase IIB Clinical Trial of the Anti-Angiogenic Drug Combination Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression free survival (PFS) measured 24 weeks after treatment initiation
24 weeks and up to 3 years
No
Dan Goldstaub, PhD
Study Director
Chief Operating Officer, Tiltan Pharma LtD
Israel: Israeli Health Ministry Pharmaceutical Administration
TLH-202
NCT00684970
March 2009
Name | Location |
---|